Boserolimab

Phase 2Monoclonal antibody

Merck & Co.

Boserolimab is one of 148 biologic programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Carcinoma, Non-Small-Cell LungCompleted

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Completed

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Boserolimab

Merck & Co.

Phase 2

5 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Treatment

GSK

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

PreclinicalRecruiting

Carcinoma, Non-Small-Cell Lung

NCT04165070

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung2 trials

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04165096·128 enrolled

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT04165070·450 enrolled

Advanced Solid Tumors1 trial

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03396445·182 enrolled

Triple-Negative Breast Cancer1 trial

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 2·NCT06829199

Small Cell Lung Cancer1 trial

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04924101·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Boserolimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Boserolimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Boserolimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Boserolimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung2 trials

Advanced Solid Tumors1 trial

Triple-Negative Breast Cancer1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News